ABSTRACT
The neurotensin receptors are attractive targets for the development of new analgesic compounds. They represent potential alternatives or adjuvants to opioids. Herein, we report the structural optimization of our recently reported macrocyclic peptide analogues of NT(8-13). The macrocycle was formed via ring-closing metathesis (RCM) between an ortho allylated tyrosine residue in position 11 and the side chain of alkene-functionalized amino acid in position 8 of NT(8-13). Minute modifications led to significant binding affinity improvement ( Ki improved from 5600 to 15 nM) with greatly improved plasma stability compared to NT(8-13). This study also delineates the structural features influencing these parameters. The signaling profiles of the new macrocycles were determined on the NTS1 receptor, and the physiological effects of the two most potent and stable analogues were assessed in vivo using rodent models. Both compounds displayed strong analgesic effects.
Subject(s)
Analgesics, Non-Narcotic/chemistry , Analgesics, Non-Narcotic/pharmacology , Neurotensin/pharmacology , Peptide Fragments/pharmacology , Peptides, Cyclic/chemistry , Receptors, Neurotensin/metabolism , Animals , Binding, Competitive , Blood Pressure/drug effects , Body Temperature/drug effects , CHO Cells , Cricetulus , Cyclization , Drug Evaluation, Preclinical/methods , Drug Stability , Male , Molecular Docking Simulation , Neurotensin/agonists , Neurotensin/chemistry , Peptide Fragments/agonists , Peptide Fragments/chemistry , Peptides, Cyclic/blood , Peptides, Cyclic/pharmacology , Rats, Sprague-Dawley , Receptors, Neurotensin/chemistry , Structure-Activity Relationship , Tyrosine/chemistryABSTRACT
The inositol 1,4,5 trisphosphate receptor (IP3R) is an intracellular Ca2+ release channel expressed predominately on the membranes of the endoplasmic reticulum. IP3R1 can be cleaved by caspase or calpain into at least two receptor fragments. However, the functional consequences of receptor fragmentation are poorly understood. Our previous work has demonstrated that IP3R1 channels, formed following either enzymatic fragmentation or expression of the corresponding complementary polypeptide chains, retain tetrameric architecture and are still activated by IP3 binding despite the loss of peptide continuity. In this study, we demonstrate that region-specific receptor fragmentation modifies channel regulation. Specifically, the agonist-evoked temporal Ca2+ release profile and protein kinase A modulation of Ca2+ release are markedly altered. Moreover, we also demonstrate that activation of fragmented IP3R1 can result in a distinct functional outcome. Our work suggests that proteolysis of IP3R1 may represent a novel form of modulation of IP3R1 channel function and increases the repertoire of Ca2+ signals achievable through this channel.
Subject(s)
Calcium Signaling , Inositol 1,4,5-Trisphosphate Receptors/metabolism , Inositol 1,4,5-Trisphosphate/metabolism , Protein Processing, Post-Translational , Amino Acid Substitution , Animals , Cell Line , Chickens , Cyclic AMP-Dependent Protein Kinases/chemistry , Cyclic AMP-Dependent Protein Kinases/metabolism , Gene Knockout Techniques , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Inositol 1,4,5-Trisphosphate Receptors/agonists , Inositol 1,4,5-Trisphosphate Receptors/chemistry , Inositol 1,4,5-Trisphosphate Receptors/genetics , Kinetics , Mutation , Patch-Clamp Techniques , Peptide Fragments/agonists , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/metabolism , Phosphorylation , Proteolysis , Rats , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Up-RegulationABSTRACT
Neurokinin B (NKB) regulates the release of gonadotropin-releasing hormone (GnRH) via activation of the neurokinin-3 receptor (NK3R). We evaluated the biological stability of NK3R selective agonists to develop novel NK3R agonists to regulate reproductive functions. On the basis of degradation profiles, several peptidomimetic derivatives were designed. The modification of senktide with (E)-alkene dipeptide isostere generated a novel potent NK3R agonist with high stability and prolonged bioactivity.
Subject(s)
Neurokinin B/analogs & derivatives , Peptide Fragments/agonists , Peptidomimetics/pharmacology , Receptors, Neurokinin-3/agonists , Substance P/analogs & derivatives , Animals , Female , Goats , Humans , Hypothalamus/metabolism , Inhibitory Concentration 50 , Ovariectomy , Peptide Fragments/classification , Peptide Fragments/metabolism , Peptide Hydrolases/metabolism , Peptidomimetics/chemistry , Protein Stability , Serum/metabolism , Substance P/agonists , Substance P/classification , Substance P/metabolism , SwineABSTRACT
Local renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further evaluated. The present study was carried out to investigate the anti-angiogenic effect of olmesartan alone or in combination with sorafenib, an angiotensin (1-7) agonist or an angiotensin (1-7) antagonist in Ehrlich's ascites carcinoma-bearing mice. The tumor was induced by intradermal injection of Ehrlich's ascites carcinoma cells into mice. Tumor discs were used to evaluate the microvessel density; the serum levels of vascular endothelial growth factor (VEGF) and serum insulin-like growth factor I (IGF-I); and their intratumoral receptors, VEGF receptor-2 and IGF-I receptor, respectively. All parameters were determined following the treatment course, which lasted for 21 days post-inoculation. Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors. In addition, the combination of olmesartan (30 mg/kg) with an angiotensin (1-7) agonist reduced the microvessel density, IGF-I serum levels and the levels of its intratumoral receptor. In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin (1-7) receptor. These results suggest that olmesartan is a promising adjuvant to sorafenib in the treatment of cancer.
Subject(s)
Carcinoma, Ehrlich Tumor/drug therapy , Imidazoles/pharmacology , Niacinamide/analogs & derivatives , Phenylurea Compounds/pharmacology , Tetrazoles/pharmacology , Angiotensin I/agonists , Angiotensin I/antagonists & inhibitors , Angiotensin I/physiology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Antineoplastic Agents/pharmacology , Carcinoma, Ehrlich Tumor/metabolism , Carcinoma, Ehrlich Tumor/physiopathology , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Drug Synergism , Female , Immunohistochemistry , Insulin-Like Growth Factor I/metabolism , Mice , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/physiopathology , Neovascularization, Pathologic/prevention & control , Niacinamide/pharmacology , Peptide Fragments/agonists , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/physiology , Receptor, IGF Type 1/metabolism , Sorafenib , Tumor Burden/drug effects , Vascular Endothelial Growth Factor A/blood , Vascular Endothelial Growth Factor Receptor-2/metabolismABSTRACT
BACKGROUND AND AIMS: Resveratrol, the most investigated dietary compound in studies aimed at linking wine consumption to human health, is an extremely minor component of this beverage and it is generally studied in vitro as the unconjugated aglycone at concentrations largely exceeding those found in the human circulatory system after dietary intake. Moreover, following intestinal absorption, trans-resveratrol and its glucoside, which are naturally present in wine and other food sources, are converted to sulphate and glucuronide metabolites. An estrogenic activity has previously been documented for resveratrol, yet nothing is known about the activity of its blood-circulating metabolic derivatives. METHODS AND RESULTS: Using a yeast two-hybrid detection system relying on the interaction between the ligand-binding domain of the human oestrogen receptors α and ß and the human coactivator Tif2, we have systematically examined the oestrogen agonist and antagonist activities of the two main resveratrol forms present in planta (trans-resveratrol and trans-resveratrol-3-O-glucoside) and of the three main metabolites found in human plasma (trans-resveratrol-3-O-sulphate, trans-resveratrol-3-O-glucuronide and trans-resveratrol-4'-O-glucuronide). Only resveratrol-3-O-sulphate was found to display a fairly strong and oestrogen receptor α-preferential antagonistic activity, which was confirmed in a human breast adenocarcinoma cell line containing a luciferase reporter gene under the control of an oestrogen-responsive promoter. CONCLUSIONS: We show, for the first time, that resveratrol-3-O-sulphate, but neither of its metabolites, is endowed with anti-estrogenic activity and how human metabolism of phenolic substances plays a pivotal role in modulating their biological effect.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Estrogen Antagonists/pharmacology , Estrogen Receptor alpha/antagonists & inhibitors , Estrogen Receptor beta/antagonists & inhibitors , Neoplasm Proteins/antagonists & inhibitors , Stilbenes/pharmacology , Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/metabolism , Binding Sites , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Cell Line, Tumor , Clone Cells , Estrogen Antagonists/chemistry , Estrogen Antagonists/metabolism , Estrogen Receptor alpha/agonists , Estrogen Receptor alpha/genetics , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/agonists , Estrogen Receptor beta/genetics , Estrogen Receptor beta/metabolism , Female , Glucosides/chemistry , Glucosides/metabolism , Glucosides/pharmacology , Glucuronides/chemistry , Glucuronides/metabolism , Glucuronides/pharmacology , Humans , MCF-7 Cells , Neoplasm Proteins/agonists , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Nuclear Receptor Coactivator 2/agonists , Nuclear Receptor Coactivator 2/antagonists & inhibitors , Nuclear Receptor Coactivator 2/genetics , Nuclear Receptor Coactivator 2/metabolism , Peptide Fragments/agonists , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/genetics , Peptide Fragments/metabolism , Phytoestrogens/chemistry , Phytoestrogens/metabolism , Phytoestrogens/pharmacology , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Resveratrol , Stereoisomerism , Stilbenes/chemistry , Stilbenes/metabolism , Sulfates/chemistry , Sulfates/metabolism , Sulfates/pharmacologyABSTRACT
The expression of the Receptor for Advanced Glycation Endproducts (RAGE) is upregulated at sites of vascular inflammation and plays a crucial role in vessel homeostasis. Soluble RAGE (sRAGE), a truncated soluble form of the receptor, acts as a decoy and prevents the inflammatory response mediated by RAGE activation. sRAGE has recently emerged as a biomarker in several RAGE-mediated vascular disorders, including coronary artery disease, hypertension, diabetic vasculopathy and Kawasaki disease. Given the pivotal role played by RAGE and sRAGE in numerous vascular disorders, there is a growing need to understand how drugs can modulate the RAGE axis in different disease conditions. In this regard, there is evidence to suggest that traditional cardiovascular drugs (statins, thiazolidinediones, ACE-inhibitors, AT-1 receptor antagonists) as well as nutraceuticals (grape seed proanthocyanidin extract) could modulate RAGE expression and circulating sRAGE levels in cardiovascular disease states characterized by enhanced RAGE activation. Additionally, the production of genetically engineered sRAGE may hold promise for targeting the activation of RAGE by proinflammatory ligands in the setting of vascular inflammation. The present review considers current vascular drugs as modulators of the RAGE axis, and highlights future directions in the context of RAGE-directed therapy in cardiovascular disease.
Subject(s)
Receptors, Immunologic/agonists , Receptors, Immunologic/antagonists & inhibitors , Vasculitis/drug therapy , Alternative Splicing , Animals , Biomarkers/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/therapy , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/physiopathology , Gene Expression Regulation , Glycation End Products, Advanced/metabolism , Humans , Peptide Fragments/agonists , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/metabolism , Peptide Fragments/therapeutic use , Phytotherapy , Protein Isoforms/agonists , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Protein Isoforms/therapeutic use , Protein Processing, Post-Translational , Receptor for Advanced Glycation End Products , Receptors, Immunologic/metabolism , Receptors, Immunologic/therapeutic use , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/therapeutic use , Solubility , Vasculitis/physiopathologyABSTRACT
Once-daily s.c. administration of either human parathyroid hormone (PTH)-(1-84) or recombinant human PTH-(1-34) provides for dramatic increases in bone mass in women with postmenopausal osteoporosis. We initiated a program to discover orally bioavailable small molecule equivalents of these peptides. A traditional high-throughput screening approach using cAMP activation of the PTH/PTH-related peptide receptor (PPR) as a readout failed to provide any lead compounds. Accordingly, we designed a new screen for this receptor that used a modified N-terminal fragment of PTH as a probe for small molecule binding to the transmembrane region of the PPR, driven by the assumption that the pharmacological properties (agonist/antagonist) of compounds that bound to this putative signaling domain of the PPR could be altered by chemical modification. We developed DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the PPR, and characterized its activity in ex vivo and in vivo assays of bone resorption. In addition, we studied its ability to initiate gene transcription by using microarray technology. Together, these experiments indicated that the highly modified 14 amino acid peptide induces qualitatively similar biological responses to those produced by PTH-(1-34), albeit with lower potency relative to the parent peptide. Encouraged by these data, we performed a screen of a small compound collection by using DPC-AJ1951 as the ligand. These studies led to the identification of the benzoxazepinone SW106, a previously unrecognized small molecule antagonist for the PPR. The binding of SW106 to the PPR was rationalized by using a homology receptor model.
Subject(s)
Molecular Probes/physiology , Oxazepines/pharmacology , Parathyroid Hormone/physiology , Peptide Fragments/physiology , Receptor, Parathyroid Hormone, Type 1/antagonists & inhibitors , Amino Acid Sequence , Animals , Binding, Competitive , Cell Line , Drug Evaluation, Preclinical , Humans , Male , Molecular Probe Techniques , Molecular Sequence Data , Oxazepines/agonists , Parathyroid Hormone/agonists , Parathyroid Hormone/metabolism , Peptide Fragments/agonists , Peptide Fragments/metabolism , Protein Binding , Rats , Rats, Sprague-Dawley , Receptor, Parathyroid Hormone, Type 1/agonists , Receptor, Parathyroid Hormone, Type 1/metabolismABSTRACT
Peptides of the endozepine family, including diazepam-binding inhibitor, the triakontatetraneuropeptide, and the octadecaneuropeptide (ODN), act through three types of receptors, that is, central-type benzodiazepine receptors (CBR), peripheral-type (mitochondrial) benzodiazepine receptors (PBR) and a metabotropic receptor positively coupled to phospholipase C via a pertussis toxin-sensitive G protein. We have previously reported that ODN exerts a potent anorexigenic effect in rat and we have found that the action of ODN is not affected by the mixed CBR/PBR agonist diazepam. In the present report, we have tested the possible involvement of the metabotropic receptor in the anorexigenic activity of ODN. Intracerebroventricular administration of the C-terminal octapeptide (OP) and its head-to-tail cyclic analog cyclo(1-8)OP (cOP) at a dose of 100 ng mimicked the inhibitory effect of ODN on food intake in food-deprived mice. The specific CBR antagonist flumazenil and the PBR antagonist PK11195 did not prevent the effect of ODN, OP, and cOP on food consumption. In contrast, the selective metabotropic endozepine receptor antagonist cyclo(1-8)[DLeu(5)]OP (100-1000 ng; cDLOP) suppressed the anorexigenic effect of ODN, OP, and cOP. At the highest concentration tested (1000 ng), cDLOP provoked by itself a significant increase in food intake. Taken together, the present results indicate that the anorexigenic effect of ODN and OP is mediated through activation of the metabotropic receptor recently characterized in astrocytes. The data also suggest that endogenous ODN, acting via this receptor, exerts an inhibitory tone on feeding behavior.
Subject(s)
Anorexia/metabolism , Appetite Regulation/physiology , Appetite/physiology , Diazepam Binding Inhibitor/metabolism , Hypothalamus/metabolism , Neuropeptides/metabolism , Peptide Fragments/metabolism , Receptors, G-Protein-Coupled/metabolism , Receptors, Neuropeptide/metabolism , Animals , Anorexia/chemically induced , Anorexia/physiopathology , Appetite/drug effects , Appetite Regulation/drug effects , Diazepam Binding Inhibitor/agonists , Diazepam Binding Inhibitor/chemistry , Dose-Response Relationship, Drug , Flumazenil/pharmacology , Food Deprivation/physiology , GABA Modulators/pharmacology , GABA-A Receptor Antagonists , Isoquinolines/pharmacology , Male , Mice , Motor Activity/drug effects , Motor Activity/physiology , Neuropeptides/agonists , Neuropeptides/chemistry , Peptide Fragments/agonists , Peptide Fragments/chemistry , Peptides/chemistry , Peptides/pharmacology , Receptors, G-Protein-Coupled/drug effects , Receptors, GABA-A/metabolism , Receptors, Neuropeptide/drug effectsABSTRACT
The Melanocortin-4 Receptor is a G-protein coupled receptor that has been physiologically linked to participate in the regulation of energy homeostasis. The Melanocortin-4 Receptor is stimulated by endogenous melanocortin agonists derived from the pro-opiomelanocortin gene transcript and antagonized by the endogenous antagonist agouti-related protein. Central administration of melanocortin agonists has been demonstrated to decrease food intake and conversely, treatment with antagonists resulted in increased food intake. Deletion of the Melanocortin-4 Receptor gene from the mouse genome results in an obese and hyperphagic phenotype. Polymorphisms of the human Melanocortin-4-Receptor have been found in severely obese individuals, suggesting that Melanocortin-4 Receptor malfunction might be involved in human obesity and obesity-associated diabetes. Herein, we have performed experiments to understand the molecular mechanisms associated with the L250Q human Melanocortin-4-Receptor polymorphism discovered in an extremely obese woman. This L250Q human Melanocortin-4-Receptor has been pharmacologically characterized to result in a constitutively active receptor. The fact that a constitutively active human Melanocortin-4-Receptor mutation was found in an obese person is a physiologic contradiction, as chronic activation of the human Melanocortin-4-Receptor and subsequently high cyclic adenosine monophosphate levels should theoretically result in a normal or lean phenotype. In this study, we demonstrated that agouti-related protein acts as an inverse agonist at this constitutively active receptor, and we propose a mechanism by which agouti-related protein might contribute to the obese phenotype in the L250Q patient. In addition, using receptor mutagenesis, pharmacology, and computer modeling approaches, we investigated the molecular mechanism by which modification of the L250 residue results in constitutive activation of the human Melanocortin-4-Receptor.
Subject(s)
Amino Acid Substitution/genetics , Gene Expression Regulation , Leucine/genetics , Polymorphism, Genetic , Receptor, Melanocortin, Type 4/genetics , Receptor, Melanocortin, Type 4/metabolism , Agouti-Related Protein , Amino Acid Sequence , Amino Acid Substitution/physiology , Animals , Cell Line , Cell Membrane/chemistry , Cell Membrane/genetics , Cell Membrane/metabolism , Female , Glutamine/genetics , Humans , Hypothalamus/metabolism , Leucine/physiology , Male , Molecular Sequence Data , Mutagenesis, Site-Directed , Peptide Fragments/agonists , Peptide Fragments/antagonists & inhibitors , Protein Conformation , Rats , Rats, Sprague-Dawley , Receptor, Melanocortin, Type 4/physiologyABSTRACT
Glucagon-like peptide-1 (GLP-1) is a peptide hormone from the gut that stimulates insulin secretion and protects beta-cells, inhibits glucagon secretion and gastric emptying, and reduces appetite and food intake. In agreement with these actions, it has been shown to be highly effective in the treatment of Type 2 diabetes, causing marked improvements in glycaemic profile, insulin sensitivity and beta-cell performance, as well as weight reduction. The hormone is metabolised rapidly by the enzyme dipeptidyl peptidase IV (DPP-IV) and, therefore, cannot be easily used clinically. Instead, resistant analogues of the hormone (or agonists of the GLP-1 receptor) are in development, along with DPP-IV inhibitors, which have been demonstrated to protect the endogenous hormone and enhance its activity. Agonists include both albumin-bound analogues of GLP-1 and exendin-4, a lizard peptide. Clinical studies with exendin have been carried out for > 6 months and have indicated efficacy in patients inadequately treated with oral antidiabetic agents. Orally active DPP-IV inhibitors, suitable for once-daily administration, have demonstrated similar efficacy. Diabetes therapy, based on GLP-1 receptor activation, therefore, appears very promising.
Subject(s)
Adenosine Deaminase Inhibitors , Diabetes Mellitus, Type 2/drug therapy , Glucagon/analogs & derivatives , Glucagon/physiology , Glycoproteins/antagonists & inhibitors , Hypoglycemic Agents/therapeutic use , Peptide Fragments/physiology , Protein Precursors/physiology , Receptors, Glucagon/agonists , Adenosine Deaminase/physiology , Afferent Pathways/physiology , Animals , Appetite/drug effects , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Dipeptidyl Peptidase 4/physiology , Drug Therapy, Combination , Exenatide , Glucagon/agonists , Glucagon/metabolism , Glucagon/pharmacology , Glucagon/therapeutic use , Glucagon-Like Peptide 1 , Glucagon-Like Peptide-1 Receptor , Glycoproteins/physiology , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/pharmacology , Hypothalamus/drug effects , Hypothalamus/physiopathology , Insulin/biosynthesis , Insulin/genetics , Insulin/metabolism , Insulin Secretion , Intestinal Mucosa/innervation , Intestinal Mucosa/metabolism , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Liraglutide , Lizards , Maleimides/therapeutic use , Mice , Mice, Knockout , Mice, Obese , Peptide Fragments/agonists , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Peptides/pharmacology , Peptides/therapeutic use , Proglucagon , Protein Precursors/agonists , Protein Precursors/metabolism , Protein Precursors/pharmacology , Rats , Rats, Zucker , Receptors, Glucagon/deficiency , Receptors, Glucagon/physiology , Venoms/pharmacology , Venoms/therapeutic useABSTRACT
Unilateral microinjection of Angiotensin-(1-7)[Ang-(1-7)] into the rostral ventrolateral medulla (RVLM) of anesthetized rats caused an increase in mean arterial pressure (MAP) accompanied by an increased release of excitatory amino acid (EAA) glutamate. In contrast, microinjection of Ang779, a selective antagonist of Ang-(1-7) receptor, into the RVLM caused a decrease in MAP accompanied by a deceased release of EAA glutamate as well as an increased release of inhibitory amino acid (IAA) glycine, taurine and gamma-aminobutyric acid. After electroacupuncture (EA) stimulation at "Zusanli"(St.36) for 20 min, the above effects of Ang-(1-7) or Ang779 attenuated. These results suggest that attenuation of EA on the pressor effect of Ang-(1-7) or the depressor effect of Ang779 may be through regulating the corresponding amino acid neurotransmitter release in the RVLM.
Subject(s)
Angiotensin I/pharmacology , Antihypertensive Agents/pharmacology , Electroacupuncture , Medulla Oblongata/metabolism , Neurotransmitter Agents/metabolism , Peptide Fragments/pharmacology , Transfer RNA Aminoacylation , Angiotensin I/agonists , Animals , Blood Pressure/drug effects , Brain Chemistry/drug effects , Electroacupuncture/methods , Excitatory Amino Acids/metabolism , Heart Rate/drug effects , Hypertension/drug therapy , Hypertension/metabolism , Injections, Intraventricular , Male , Microdialysis , Microinjections , Peptide Fragments/agonists , Rats , Rats, WistarABSTRACT
High concentrations of glucagon-like peptide-1 (7-36) amide (GLP-1) and its specific receptor (GLP-1R) have been found in the rat hypothalamus. In this study the actions of GLP-1 and its related peptides, exendin-4 (GLP-1R agonist), exendin (9-39) (GLP-1R antagonist) and GLP-1 (9-36) amide (the major GLP-1 metabolite) on levels of serotonin (5-HT), 5-hydroxyindolacetic acid (5-HIAA) and amino acids (Glu, Asp, Gln, Gly, Tyr, Trp, GABA) in the hypothalamus were investigated. Intracerebroventricular (ICV) injection of GLP-1 (4 nmol) produced a significant reduction in levels of 5-HT (54%) and all measured amino acids (34 to 56%) compared with saline injected controls, whereas exendin (9-39) (4 nmol) was ineffective. ICV injection of exendin-4 produced a significant reduction in the levels of 5-HT, 5-HIAA, Trp, Glu, and Tyr. ICV injection of GLP-1(9-36) amide showed a statistically significant increase in the level of 5-HT, 5-HIAA and all the amino acids tested in this study. Prior administration of exendin (9-39) or GLP-1 (9-36) amide blocked the effects of GLP-1 on the levels of 5-HT and the amino acids. These data are consistent with exendin-4 being a GLP-1R agonist and exendin (9-39) being a specific GLP-1R antagonist. GLP-1 (9-36) amide, a primary metabolite of GLP-1, appears to act as an endogenous antagonist at the GLP-1R.